Adagene Inc. has announced a strategic partnership with ConjugateBio Inc. to advance the development of novel antibody drug conjugates (ADCs). As part of the agreement, Adagene will supply a proprietary antibody for ConjugateBio's bispecific ADC programs. In return, Adagene will receive an undisclosed upfront payment, along with milestone and royalty payments, while retaining all non-ADC rights to the antibody. This collaboration aims to leverage Adagene's distinguished antibody discovery capabilities and ConjugateBio's expertise in ADC development, potentially expanding the ADC market, which is projected to exceed $30 billion by 2030.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。